The biphasic nature of nitric oxide responses in tumor biology

Antioxidants and Redox Signaling

Volumn 8, Issue 7-8, 2006, Pages 1329-1337

  Ridnour, Lisa A ^a   Thomas, Douglas D ^a   Donzelli, Sonia ^a   Espey, Michael G ^a   Roberts, David D ^a   Wink, David A ^a   Isenberg, Jeffrey S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; THROMBOSPONDIN 1;

ANGIOGENESIS; CANCER INVASION; CANCER SURVIVAL; CYTOLOGY; METASTASIS; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; BIOLOGY; BIOMIMETIC MATERIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; OXIDATION-REDUCTION; THROMBOSPONDIN 1; TIME FACTORS;

EID: 33746813720     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2006.8.1329     Document Type: Review

References (82)

1. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Harrington AM, Shields PG, Felley-Bosco E, Hussain SP, and Harris CC. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 91: 86-88, 1999.
2. Baker LH, Demetri GD, Mendelson DS, Rowinsky EK, McKeegan EM, Knight RA, Carlson DM, and Lobell M. A randomized phase 2 study of the thrombospondin- mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS). J Clin Oncol 23: 819S-819S.
3. Brune B. The intimate relation between nitric oxide and superoxide in apoptosis and cell survival. Antiox Redox Signal 1: 497-507, 2005.
4. Brune B and Mohr S. Protein thiol modification of glyceraldehyde-3- phosphate dehydrogenase and caspase-3 by nitric oxide. Curr Protein Pept Sci 2: 61-72, 2001.
5. Brune B, von Knethen K, and Sandau KB. Nitric oxide and its role in apoptosis. Eur J Pharm 351: 261-272, 1998.
6. Chen GG, Lau WY, Lai PBS, Chun YS, Chak ECW, Leung BCS, Lam IKY, Lee JFY, and Chui AKK. Activation of Kupffer cells inhibits tumor growth in a murine model system. Int J Cancer 99: 713-720, 2002.
7. Chen JX, Lawrence ML, Cunningham G, Christman BW, and Meyrick B. HSP90 and Akt modulate Ang-1-induced angiogenesis via NO in coronary artery endothelium. J Appl Physiol 96: 612-620, 2004.
8. Cooke JP. NO and angiogenesis. Atherosclerosis Suppl 4: 53-60, 2003.
9. Dawson DW, Pearce SFA, Zhong R, Silverstein RL, Frazier WA, and Bouck NP. CD36 mediates the in vitro inhibitory effects of thrombospondin1 on endothelial cells. J CellBiol 138: 707-717, 1997.
10. Duda DG, Fukumura, D, and Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 10: 143-145, 2004
11. Ebbinghaus SW, Hussain M, Tannir NM, Gordon MS, Desai AA, Knight RA, Carlson DM, Figlin RA. A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma. J Clin Oncol 23: 404S-404S, 2005.
12. Ekmekcioglu S, Tang CH, and Grimm EA. NO news is not necessarily good news in cancer. Curr Cancer Drug Targets 5: 103-115, 2005.
13. Espey MG, Miranda KM, Pluta, RM, and Wink DA. Nitrosative capacity of macrophages is dependent on nitric oxide synthase induction signals. J Biol Chem 275: 11341-11347, 2000.
14. Florian M, Lu Y, Angle M, and Magder S. Estrogen induced changes in Akt-dependent activation of endothelial nitric oxide synthase and vasodilation. Steroids 69: 637-645, 2004.
15. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 3: 643-651, 2003.
16. Fulton D, Fontana J, Sowa G, Gratton JP, Lin M, Li KX, Michell B, Kemp B, Rodman D, and Sessa WC. Localization of endothelial nitric oxide synthase phosphorylated on serine 1179 and nitric oxide in Golgi and plasma membrane defines the existence of two pools of active enzyme. J Biol Chem 277: 4277-4284, 2002.
17. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, and Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597-601, 1999.
18. Fulton D, Gratton JP, and Sessa WC. Post-translational control of endothelial nitric oxide synthase: Why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 299: 818-824, 2001.
19. Gasparini G, Longo R, Fanelli M, and Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions. J Clin Oncol 23: 1295-311, 2005.
20. Goodman J, Hofseth LJ, Hussain SP, and Harris CC. Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen 44: 3-9, 2004.
21. Greif DM, Kou R, and Michel T. Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: Evidence for crosstalk between phosphorylation sites. Biochemistry 41: 15845-15853, 2002.
22. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, and Kalluri R. Thrombospondin1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64: 1570-1574, 2004.
23. Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM, McKay LM, Haskell CJ, Bell RL, Nguyen B, Marsh KC, Surber BW, Uchic JT, Ferrero J, Wang YC, Leal J, Record RD, Hodde J, Badylak SF, Lesniewski RR, and Henkin J. Thrombospondin1 mimetic peptide inhibitors of angiogenesis and tumor growth: Design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 48: 2838-2846, 2005.
24. Hibbs JB, Taintor, RR, and Vavrin Z. Macrophage cytotoxicity: Role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 235: 473-476, 1987.
25. Hoekstra R, de Vos FYFL, Eskens FALM, Gietema JA, van der Gaast A, Groen HJM, Knight RA, Carr RA, Humerickhouse RA, Verweij J, and de Vries EGE. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondinl- mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 23: 5188-5197, 2005.
26. Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, and Harris CC. Nitric oxide induced cellular stress and P53 activation in chronic inflammation. Proc Natl Acad Sci USA 100: 143-148, 2003.
27. Russian SP, Trivers GE, Hofseth LJ, He P, Shaikh I, Mechanic LE, Doja S, Jiang W, Subleski J, Shorts L, Haines D, Laubach VE, Wiltrout RH, Djurickovic D, and Harris CC. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res 64: 6849-6853, 2004.
28. Igarashi J and Michel T. Sphingosinel-phosphate and isoform-specific activation of phosphoinositide 3-kinase. J Biol Chem 276: 36281-36288, 2001.
29. Iruela-Arispe LM, Lombarde M, Krutzsch HC, Lawler J, and Roberts DD. Inhibition of angiogenesis by thrombospondin1 is mediated by two independent regions within the type 1 repeats. Circulation 100: 1423-1431, 1999.
30. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, and Roberts DD. Thrombospondin1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 102: 13141-13146, 2005.
31. Jadeski LC, Chakraborty C, and Lala PK. Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase. Int J Cancer 106: 496-504, 2003.
32. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, and Moncada S. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92: 4392-4396, 1995.
33. Jones MK, Tsugawa K, Tarnawski AS, and Baatar D. Dual actions of nitric oxide on angiogenesis: Possible roles of PKC, ERK, and AP-1. Biochem Biophys Res Commun 318: 520-528, 2004.
34. Kashiwagi S, Izumi Y, Gohongi T, Demou ZN, Xu L, Huang PL, Buerk DG, Munn LL, Jain, RK, and Fukumura D. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest 115: 1816-1827, 2005.
35. Kim SJ, Hwang, SG, Shin DY, Kang SS, and Chun JS. p38 kinase regulates nitric oxide induced apoptosis of articular chondrocytes by accumulating p53 via NFkB-dependent transcription and stabilization by serine 15 phosphorylation. J Biol Chem 277: 33501-33508, 2002.
36. Kim YM, Talanian RV, and Billiar TR. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 111: 31138-31148, 1997.
37. Kuznetsova SA and Roberts DD. Functional regulation of T lymphocytes by modulatory extracellular matrix proteins. Int J Biochem Cell Biol 36: 1126-1134, 2004.
38. Lala PK and Orucevic A. Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev 17: 91-106, 1998.
39. Lawler, J. Thrombospondinl as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6: 1-12, 2002.
40. Lawler J and Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 36: 1038-1045, 2004.
41. Le X, Wei D, Huang S, Lancaster JR Jr, and Xie K. Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of pro-tumor factors. Proc Natl Acad Sci U SA 102: 8758-8763, 2005.
42. Lechner M, Lirk, P, and Rieder J. Inducible nitric oxide (iNOS) in tumor biology: The two sides of the same coin. Semin Cancer Biol 15: 277-289, 2005.
43. Li J, Billiar TR, Talanian RV, and Kim YM. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem Biophys Res Commun 240: 419-424, 1997.
44. Li Z, He L, Wilson KE, and Roberts DD. Thrombospondin1 inhibits TCR-mediated T lymphocyte early activation. J Immunol 166: 2427-2436, 2001.
45. McCabe TJ, Fulton D, Roman LJ, and Sessa WC. Enhanced electron flux and reduced calmodulin dissociation may explain "calcium-independent" eNOS activation by phosphorylation. J Biol Chem 275: 6123-6128, 2000.
46. Meßmer UK, Ankarcrona M, Nicotera P, and Brüne B. P53 Expression in nitric oxide-induced apoptosis. FEBS Lett 355: 23-26, 1994.
47. Metzen E, Zhou J, Jelkmann W, Fandrey J, and Brüne B. Nitric oxide impairs normoxic degradation of HIF-1α by inhibition of prolyl hydroxylases. Mol Biol Cell 14: 3470-3481, 2003.
48. Mohr S, Zech B, Lapetina EG, and Brüne B. Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide. Biochem Biophys Res Commun 238: 387-391, 1997.
49. Palmer L, Gaston B, and Johns RA. Normoxic stabilization of hypoxia-inducible factor-1 expression and activity: Redox-dependent effect of nitrogen oxides Mol Pharm 58: 1197-1203, 2000.
50. Pervin S, Singh R, Freije WA, and Chaudhuri G. MKP1-induced dephosphorylation of extracellular signal-regulated kinase is essential for triggering nitric oxide-induced apoptosis in human breast cancer cell lines: Implications in breast cancer. Cancer Res 63: 8853-8860, 2003.
51. Ridnour LA, Isenberg JS, Espey MD, Thomas DD, Roberts DD, and Wink DA. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin1. Proc Natl Acad Sci U S A 102: 13147-13152, 2005.
52. Ridnour LA, Oberley TD, and Oberley LW. Tumor suppressive effects of MnSOD overexpression may involve imbalance in peroxide generation versus peroxide removal. Antiox Redox Signal 6: 501-512, 2004.
53. Ridnour LA, Sim JE, Choi J, Dickinson DA, Forman HJ, Ahmad IM, Coleman MC, Hunt CR, Goswami PC, and Spitz DR. Nitric oxide-induced resistance to hydrogen peroxide stress is a glutamate cysteine ligase activity-dependent process. Free Radic Biol Med 38: 1361-1371, 2005.
54. Ridnour LA, Thomas DD, Mancardi D, Espey MG, Miranda KM, Paolocci N, Feelisch M, Fukuto J, and Wink DA. The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species: Putting perspective on stressful biological situations. Biol Chem 385: 1-10, 2004.
55. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin1. FASEB J 10: 1183-1191, 1996.
56. Schmid T, Zhou J, and Brune B. HIF-1 and P53: Communication of transcription factors under hypoxia. J Cell Mol Med 4: 423-431, 2004.
57. Schneiderhan N, Budde A, Zhang Y, and Brune B. Nitric oxide induces phosphorylation of P53 and impairs nuclear export. Oncogene 22: 2857-2868, 2003.
58. Schwentker A, Vodovotz Y, Weller R, and Billiar TR. Nitric oxide and wound repair: Role of cytokines? Nitric Oxide 7: 1-10, 2002.
59. Sengupta K, Banerjee S, Saxena NK, and Banerjee SK. Thombospondin1 disrupts estrogen-induced endothelial cell proliferation and migration and its expression is suppressed by estradiol. Mol Cancer Res 2: 150-158, 2004.
60. Stuehr DJ. Structure-function aspects in the nitric oxide synthases. Annu Rev Pharmacol Toxicol 37: 339-359, 1997.
61. Stuehr DJ, Santolini J, Wang ZQ, Wei CC, and Adak S. Update on mechanism and catalytic regulation in the NO synthases. J Biol Chem 279: 36167-36170, 2004.
62. - cogeneration: Mechanistic considerations. Eur J Pharm 444: 1-11, 2002.
63. Takahashi S and Mendelsohn ME. Synergistic activation of endothelial nitric oxide synthase (eNOS) by HSP90 and Akt. J Biol Chem 278: 30821-30827, 2003.
64. Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, and Wink DA. Hypoxic inducible factor 1a, extracellular signal-regulated kinase, and P53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA 101: 8894-8899, 2004.
65. Thomsen LL and Miles DW. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev 17: 107-118, 1998.
66. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, and Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin1 have anti-angiogenic activity. J Cell Biol 122: 497-511, 1993.
67. Urbich C, Reissner A, Chavakis E, Dernbach E, Haendeler J, Fleming I, Zeiher AM, Kaszkin M, and Dimmeler S. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J 16: 706-708, 2002.
68. Wang S, Shiva S, Poczatek MH, Darley-Usmar V, and Murphy-Ullrich JE. Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-β activation in mesangial cells. J Biol Chem 277: 9880-9888, 2002.
69. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, and Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci US Curr 91: 5212-5216, 1994.
70. Westphal HR. Technology evaluation: ABT-510, Abbott. Curr Opin Mol Ther 6: 451-459, 2004.
71. Wink DA, Cook JA, Pacelli R, Liebmann J, Krishna MC, and Mitchell JB. Nitric oxide (NO) protects against cellular damage by reactive oxygen species. Toxicol Lett 82: 83: 221-226, 1995.
72. Wink DA and Mitchell JB. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med 25: 434-456, 1998.
73. Wink DA and Mitchell JB. Nitric oxide and cancer: an introduction. Free Radic Biol Med 34: 951-954, 2003.
74. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, and Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19: 711-721, 1998.
75. Xie K, Huang S, Dong Z, Gutman M, and Fidler IJ. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Cancer Res 55: 3123-3131, 1995.
76. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, and Fidler IJ. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 181: 1333-1343, 1995.
77. Xie K, Huang S, Dong Z, Juang SH, Wang Y, and Fidler IJ. Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst 89: 421-427, 1997.
78. Zech B, Kohl R, von Knethen A, and Brune B. Nitric oxide donors inhibit formation of the Apaf-1/caspase-9 apoptosome and activation of caspases. Biochem J 371: 1055-1064, 2003.
79. Zech B, Wilm M, van Eldik R, and Brune B. Mass spectrometric analysis of nitric oxide-modified caspase-3. J Biol Chem 274: 20931-20936, 1999.
80. Zhou J and Brune B. NO and transcriptional regulation: from signaling to death. Toxicology 208: 223-233, 2005.
81. Zhou J, Schmid T, and Brune B. HIF-1 and P53 as targets of NO in affecting cell proliferation, death and adaptation. Curr Mol Med 4: 741-751, 2004.
82. Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, Harris CC, and Rotter V. The role of P53 in base excision repair following genotoxic stress. Carcinogenesis 25: 11-9, 2004.